We constructed an adenoviral vector containing human p16 cDNA in order to evaluate the cytotoxic eects of exogenous p16 expression on cancer cell proliferation and to explore the potential use of p16 in cancer gene therapy. Following infection of human breast (MCF-7, MDA-MB-231, and BT549), osteosarcoma (U-2 OS and Saos-2), cervical (C33a), and lung cancer (H358) cell lines with the recombinant adenovirus Adp16, high levels of p16 expression were observed in all cell lines. Cancer cell lines which were mutant or null for p16 but wild-type for the retinoblastoma gene product (pRb) (MCF-7, MDA-MB-231, BT549 and U-2 OS) were 7 ± 22-fold more sensitive to the cytotoxic eects of Adp16 than to a control virus. In contrast, cancer cell lines which were wild-type for p16 but mutant or null for pRb (Saos-2, C33a and H358) were 5threefold more sensitive to Adp16 when compared to a control virus. Analysis of 5-bromodeoxyuridine incorporation into DNA following infection with Adp16 showed a loss of S phase in those cell lines which were null or mutant for p16 but expressed a functional pRb. This cell cycle arrest was associated with binding of the p16 protein to cyclindependent kinase 4 and dephosphorylation of pRb. In contrast, human cancer cell lines expressing a wild-type p16 and a mutant pRb or no pRb showed no substantial loss of S phase following Adp16 infection. Based on these studies, we conclude that p16-mediated cytotoxicity is tightly associated with the presence of functional pRb in human cancer cells, and that tumor cells which are mutant or null for p16 are candidates for Adp16 mediated cancer gene therapy.
Introduction
There have been signi®cant advances in recent years in our understanding of the cell cycle and in the genes expressing cell cycle regulatory proteins including cyclins, cyclin dependent kinases (Cdks), Cdk activating kinases, and cyclin dependent kinase inhibitors (CDKIs) (Solomon, 1993; Elledge and Harper, 1994; Aprelikova et al., 1995; Hall et al., 1995; Sherr and Roberts 1995; Grana and Reddy, 1995) . These include the tumor suppressor genes Rb (Lee et al., 1987; Mihara et al., 1989) and p53 (Chen et al., 1990; Levine et al., 1991; Dulic et al., 1994) , the universal cyclin dependent kinase inhibitors p21/WAF1/Cip1 (El-Deiry et al., 1993; Harper et al., 1993; Xiong et al., 1993b; Li et al., 1994a ) and p27 Kip1 (Polyak et al., 1994; Toyoshima and Hunter, 1994) , and other CDKIs such as p16/CDKN2/CDK4I/MTS1 (Xiong et al., 1993a; Serrano et al., 1993 Serrano et al., , 1995 Okamoto et al., 1994) , p15/ MTS2 (Hannon and Beach, 1994) and p18 (Guan et al., 1994) . The important links between altered functioning of these genes and the risk of carcinogenesis have been recently highlighted (Hunter and Pines, 1994; Kamb, 1995) .
Of particular interest is the recently characterized tumor suppressor gene p16, which maps to chromosome region 9p21 (Kamb et al., 1994; Nobori et al., 1994) . An understanding of the role of p16 in normal cell cycle regulation and carcinogenesis is of considerable importance due to the many reports of homozygous deletions of p16 in tumor-derived cell lines and mutations or deletions of p16 in some primary tumor types (reviewed in Kamb, 1995; Sherr and Roberts, 1995) . In addition to p16 mutations and deletions, other mechanisms of p16 gene silencing have been proposed, including hypermethylation and chromatin condensation (Herman et al., 1995; Costello et al., 1996; Geradts and Wilson, 1996) . A large body of work has led to a complex model of p16-mediated cell cycle control which involves multiple cell cycle regulatory molecules (Kato et al., 1993; Hannon and Beach, 1994; Okamoto et al., 1994 , Draetta 1994 Li et al., 1994b; Lukas et al., 1994a Lukas et al., ,b, 1995 Koh et al., 1995; Medema et al., 1995; Serrano et al., 1995; Parry et al., 1995) . As cyclin D levels rise in G 1 , cyclin D binds the constitutively expressed Cdks 4 and 6. This leads to the phosphorylation of the retinoblastoma gene product (pRb) and subsequent release of E2F, resulting in transcriptional activation and progression of cells through S phase. It has been proposed that in the presence of the CDKI p16, the formation of cyclin D-Cdk4/6 complexes is prevented by direct binding of p16 with Cdk4/6. Phosphorylation of pRb is thereby prevented, which in turn leads to G 1 /S arrest.
In order to further study the mechanisms of p16-mediated cell cycle arrest and to explore which tumor types might potentially be amenable to treatment with p16 gene therapy, we have constructed an adenoviral vector containing human p16 cDNA (Adp16). Infection of multiple human tumor cell lines with Adp16 led to high levels of p16 expression in all cell lines tested. Adp16 infection was cytotoxic to human cancer cell lines that expressed endogenous wild-type pRb but which were null or mutant for p16. However, cells which did not express a wild-type endogenous pRb but did express wild-type p16 were relatively less sensitive to killing by Adp16. No relationship was observed between Adp16-mediated cytotoxicity and endogenous p53 status in the cell lines tested. Adp16-induced cytotoxicity appears to be the result of a marked cell cycle arrest. This cell cycle arrest is associated with the complexing of p16 and Cdk4, which inhibits the phosphorylation of pRb by Cdk4 (Kato et al., 1993; Hannon and Beach, 1994; Okamoto et al., 1994; Draetta 1994; Li et al., 1994b; Lukas et al., 1995; Koh et al., 1995; Medema et al., 1995; Serrano et al., 1995; Parry et al., 1995) .
The results presented here suggest that perhaps there is an association between Adp16-mediated cell cycle arrest and cytotoxicity and the presence of functional pRb. In addition, cell lines which lacked functional p16 expression were more sensitive to Adp16-mediated cell cycle arrest and cytotoxicity than cell lines which expressed functional p16. These ®ndings dier from those of other studies which used other CDKI expressing adenoviruses, such as those expressing the universal CDKIs p27
Kip1 (Craig et al., 1997) or p21/ WAF1/Cip1 (Katayose et al., 1995b) , which found no relationship between the ability of the adenovirally expressed CDKIs to induce cell cycle arrest and endogenous Rb or p16 status. These ®ndings could have potential relevance in choosing appropriate tumors for gene therapy treatment with this vector.
Results

An adenovirus vector containing human p16 cDNA
In order to investigate the role of pRb in p16 INK4A mediated cell cycle arrest, an adenovirus vector containing human p16/CDKN2/CDK4I/MTS1 cDNA was constructed by homologous recombination between the shuttle vector pCC2, which contains the p16 expression cassette, and Cla1 digested adenovirus type 5 genomic DNA, as described in Materials and methods. A schematic diagram of the replication incompetent recombinant adenovirus Adp16 is shown in Figure 1 . The key elements of the p16 expression cassette include the left inverted terminal repeat (ITR), the origin of replication, adenovirus type 5 encapsidation signals and E1a enhancer, human cytomegalovirus immediate early promoter, human wild type p16 cDNA, and the SV40 RNA maturation signal.
Adp16-mediated p16 expression in human cancer cells
To investigate Adp16-mediated p16 expression in human cancer cell lines with diering endogenous p16, pRb, and p53 status (see Table 1 ), Saos-2, BT549, C33a, MCF-7, MDA-MB-231, U-2 OS, and H358 cell lines were infected with Adp16 or AdControl and p16 expression was evaluated as described in Materials and methods. As shown in Figure 2 , Adp16 infection resulted in a marked increase in p16 protein levels in all cell lines studied. In contrast, cells infected with a control adenovirus had no detectable increase in the level of p16 expression as compared to the level of a control protein (actin). These results indicate that all cell lines studied were successfully infected by Adp16 and that infection resulted in a marked increase in p16 expression. Okamoto et al., 1994; Aagaard et al., 1995; Koh et al., 1995; Lukas et al., 1995;  b Rb data from Bartek et al., 1992; Okamoto et al., 1994; Aagaard et al., 1995; Lukas et al., 1995; Koh et al., 1995;  c p53 data from Okamoto et al., 1994; Lukas et al., 1995; Katayose et al., 1995b; Bischo et al., 1996 ; Except p16 and Rb status in H358, screened by Western blot.
d Fold Dierences of Cytotoxicity of Adp16 and AdControl (see Figure 3 ). e % Inhibitions of BrdU content by Adp16 vs AdControl (n=4, see Figures 4 and 5).
f (+) Indicates wild-type protein; g (±) Indicates lack of functional protein, due to mutation, deletion, or hypermethylation
Adp16 cytotoxicity is related to endogenous p16 and Rb status
The ability of Adp16 to inhibit the growth of human cancer cells was examined as described in Materials and methods. As shown in Figure 3 , U-2OS, MDA-MB-231, MCF-7 and H358 cell lines, which express wild-type pRb but do not express functional p16 protein, were up to 22-fold more sensitive to Adp16 relative to the control adenovirus (AdControl). In contrast, the cell lines Saos-2, BT-549, and C33a, which express wild-type p16 but do not express functional pRb, showed little or no increase in sensitivity (5threefold) to Adp16 when compared to the control adenovirus. In addition, the cell line H2228, which does not express functional pRb or p16, was not sensitive to Adp16 infection. Interestingly, the cell line HepG2, which is wild-type for both pRb and p16, was only threefold more sensitive to Adp16 infection than a control adenovirus, perhaps underscoring the role of the null or mutant endogenous p16 in Adp16-mediated cytotoxocity. Furthermore, there was no apparent relationship between Adp16-mediated cytoxicity and endogenous p53 status in these cell lines (see Table 1 ). It is interesting to note that while MCF-7 cells are sensitive to Adp16, previous studies using the p53-expressing adenoviral vector AdWTp53 indicated that MCF-7 cells were resistant to cytotoxicity following infection with AdWTp53 (Katayose et al., 1995a) .
The eect of Adp16 on BrdU incorporation into DNA is dependent upon endogenous p16 and Rb status
To investigate the eects of Adp16 infection on cell cycle inhibition, BrdU incorporation into newly synthesized DNA was examined following Adp16 infection. The results of the representative pRb + cell lines H358 and U-2OS and the Rb 7 cell lines BT549 and Saos-2 are shown in Figure 4 , and are summarized in Figure 5 along Figure 2) . These results support the model that endogenous Rb status is a potential mediator of the eects of p16 on cell cycle progression. These ®ndings dier from those involving the universal CDKIs p21 and p27, where the ability of the adenovirally expressed proteins to cause cell cycle arrest was found to be independent of endogenous Rb status (Katayose et al., 1995b; Craig et al., 1997) .
Direct binding of virally expressed p16 with cyclin dependent kinase 4 and dephosphorylation of pRb
In order to further investigate the mechanisms by which p16 mediates cell cycle regulation, we examined the speci®city of p16 cyclin dependent kinase inhibition for Cdk4 . In these studies, p16
7 / Rb + cell lines (U-2OS, MCF-7, and MDA-MB-231) and p16 + /Rb 7 cell line (C33a) were infected with Adp16 or AdControl and co-immunoprecipitation of p16 and Cdk4 was performed as described in Materials and methods. As shown in Figure 6 , binding of p16 to Cdk4 was observed in each of these cell lines following infection by Adp16. The binding of p16 to Cdk4 in the p16 + /Rb 7 C33a cells line (Figure 6 ) suggests that the lack of Adp16 cytoxicity in this cell line is due to the absence of functional pRb in these cells, and not due to an inability of p16 to bind to Cdk4. In addition, Western blot analysis of MDA-MB-231, MCF-7, U-2 OS, and H358 cell lines indicated that Adp16 infection was associated with dephosphorylation of pRb ( Figure  7 ). In the AdControl infected lanes, two pRb bands are visible, representing the two pRb forms. In the Adp16 infected lanes, the upper phosphorylated bands is lost, suggesting that Adp16 infection leads to pRb dephosphorylation. Figure 4 Eect of Adp16 infection on BrdU Incorporation. Cells were exposed to 50 p.f.u./cell of Adp16 or AdControl for 48 h as described in Materials and methods. Cell lines with wild-type pRb (U-2OS and H358) show loss of S-phase. Cell lines which were not wild-type (Saos-2 and BT549) displayed no cell cycle arrest. Based on earlier studies using Adb-gal (Seth et al., 1996) , we assume that nearly 100% of cells have been infected
Discussion
In this report we show that infection of human breast cancer cells with Adp16, a recombinant adenovirus expressing p16
INK4A
, resulted in high levels of p16 expression. This marked increase in p16 levels led to cell cycle arrest in cells expressing functional endogenous pRb, but not in cells lacking a functional pRb.
Adp16 mediated p16 expression resulted in binding of p16 to Cdk4, and dephosphorylation of pRb. Furthermore, Rb status was an important determinant of sensitivity to Adp16. Cells expressing wild-type pRb were up to 22-fold more sensitive to Adp16 than to a control virus, while cells lacking functional pRb were not sensitive to Adp16, showing 5threefold sensitivity relative to the control virus. The heterogeneity in sensitivity of wild-type Rb cell lines to Adp16 may suggest that the p16-Rb pathway is more complex than the given model suggests. It is possible that other molecules are directly involved in this pathway, or that molecules which are involved in other pathways of G 1 /S arrest may indirectly in¯uence the eects of p16-mediated arrest in the wild-type Rb cell lines. There was no apparent relationship of this sensitivity to the endogenous p53 status in the cell lines tested.
The ®nding that wild-type endogenous pRb expression is a critical determinant of p16-mediated cell cycle arrest is consistent with results obtained using plasmid vectors for transfer of p16
INK4A to cancer cells (Arap et al., 1995; Koh et al., 1995; Serrano et al., 1995; Spillare et al., 1996) . We chose to use adenoviral vectors to investigate the mechanisms of p16 mediated eects on cell cycle and cytotoxicity, because adenoviral vectors are capable of nearly 100% transduction eciency in almost all cancer cells of epithelial origin (Seth et al., 1986; . Previous studies using adenoviral vectors have shown that p16 has a negative eect on some cancer cell proliferation (Jin et al., 1995; Fueyo et al., 1996; Sandig et al., 1997) . However, in the current study we have shown clear evidence of the role that functional pRb plays in p16-mediated cell cycle arrest in human cancer cells. Furthermore, we have observed that cancer cells containing wild-type p53 are sensitive to Adp16, providing they also contain functional pRb and lack functional p16. This is of particular interest due to the ®ndings of previous studies in our laboratory which have shown that the p53
7 MCF-7 cells are resistant to adenoviral vectors expressing p53 (Katayose et al., 1995a) , p21/WAF1 (Katayose et al., 1995b) , and p27
Kip1 (Craig et al., 1997) . These results suggest that Adp16 may be useful for gene therapy of cancers which contain wild-type p53 and pRb, but where functional impairment of p16 expression either through mutation (reviewed in Kamb, 1995; Sherr and Roberts, 1995) or gene silencing (Herman et al., 1995; Costello et al., 1996) .
One issue worth discussing is the variation in viral dosage and time of exposure that exists between the dierent experiments. This derives from the fact that dierent endpoints are being examined in each experiment, and that the assays being used vary in their sensitivites. In the BrdU incorporation experiments, the endpoint being examined is cell cycle arrest. A relatively low (50 p.f.u./cell) dose was used for 48 h in order to allow adequate amounts of the transgene to be expressed and arrest to take place. The samples were then analysed by¯ow cytometry, which is a very sensitive method of detection. The Western blot uses the same dosage and time in order to demonstrate that adequate transgene product is being expressed in order to account for any observed cell cycle arrest. The CoIP experiments, however, require a larger dose of virus (200 p.f.u./cell) for a shorter time period (24 h). This is because the Cdk4 activity must be nearly completely Figure 7 Dephosphorylation of pRb following Adp16 infection. Cells were exposed to 50 p.f.u./cell of Adp16 or AdControl for 48 h as described in Materials and methods, and subjected to Western blot analysis for pRb and actin proteins lost before inhibition can be demonstrated; it is a decidedly weaker assay. Finally, the cytotoxicity experiments measure cell death as an endpoint. Cells are exposed to a wide range of viral doses for one week, and the IC 50 for each cell line is determined.
Cyclin kinase inhibitors which block cell cycle progression in G1 and induce cytotoxicity in tumor cells have been previously indicated as potentially useful candidate genes for cancer gene therapy (Hunter and Pines, 1994; Gottesman, 1994; Kamb, 1995; Katayose et al., 1995b; Craig et al., 1997) . The results presented in this report suggest that p16 represents a good candidate for cancer gene therapy. Moreover, Adp16 may also be used in combined gene therapy/chemotherapy strategies where growth arrested cells could be induced to undergo apoptosis by other means. Since Adp16 is replication-incompetent, can be grown to high titers, and can enter cells by an ecient receptor-mediated endocytosis pathway, it represents an attractive vector for gene therapy (Jones and Schenk, 1979; Seth et al., 1986; Ginsberg, 1988; Graham and Prevec, 1991; Katayose et al., 1995a,b) . Future experiments will be directed toward evaluating the in vivo eects of Adp16 in comparison with other recombinant adenoviral vectors that express wild-type p53 (AdWTp53) (Katayose et al., 1995a) and the universal Cdk inhibitors p21/WAF1/Cip1 (AdWAF1) (Katayose et al., 1995b) and p27/Kip1 (Adp27) (Craig et al., 1997) .
Materials and methods
Adenovirus vectors
A recombinant adenovirus containing human p16 cDNA (Adp16) was constructed by homologous recombination using methods described previously (Katayose et al., 1995b) . In brief, a 35 Kb adenovirus backbone derived from adenovirus type 5 of 9.24 ± 100 mu was isolated from AdWTp53 (described in Katayose et al., 1995a) by methods described previously (Graham and Prevec, 1991) . The adenovirus backbone was co-transfected with the shuttle vector pCC2 which contains the p16 expression cassette in transformed human embryonic kidney cells 293 (ATCC CRL1573) by calcium phosphate precipitation (Gibco BRL, Gaithersburg, MD). Adenoviral plaques were collected and subjected to another cycle of infection in 293 cells. Plaques were screened for the presence of p16 sequences by polymerase chain reaction (PCR) using a set of primers which were 5'-AGCCCAACTGCGCCGAC and 3'-AGACGGGACCTGGACC. PCR reactions were also performed to screen against the excised p53 expression cassette sequences. Replication assays were performed to rule out the presence of revertant adenoviruses. The key genomic elements present in Adp16 are shown in Figure 1 . The control adenovirus (AdControl) used in this study was identical to Adp16 except that it was devoid of any cDNA. adenovirus-transformed human embryonic kidney cells, were cultured in Improved Minimal Essential Medium (Gibco BRL, Gaithersburg, MD) containing 10% fetal bovine serum (FBS) (BioFluids, Rockville, MD) as described previously (Katayose et al., 1995a,b) .
Western blot analysis
Cells (1610 6 ) were plated in 10 cm dishes and incubated at 378C with 50 p.f.u./cell of adenovirus vectors for 48 h. Cells were collected by gentle scraping. Whole cell lysates were subjected to Western blot analysis as previously described (Katayose et al., 1995a,b) . Blots were probed with 3 mg/ml of antibody reactive against p16 (Ab-2; Santa Cruz, CA), actin protein (C4; Boehringer Mannheim, Indianapolis, IN), or pRb (G3-245; Pharmingen, San Diego, CA).
Cytotoxicity assays
Cells were plated in triplicate in 96-well dishes (500 cells/ well) and incubated for 24 h at 378C. Cells were then exposed to varying concentrations of Adp16 and AdControl, and incubated for 7 days at 378C. A colorimetric assay was performed as described previously (Skehan et al., 1990) . Brie¯y, cells were ®xed in 10% trichloroacetic acid for 1 h, washed ®ve times with water and allowed to air dry. Cells were then stained for 10 min with 0.4% sulphorhodamine B (Sigma, St. Louis, MO) dissolved in 1% acetic acid, and rinsed ®ve times with 1% acetic acid. Absorbance (A 564 ) was obtained using a BioKinetics Reader EL340 (Bio-Tek Instruments), which was used as a measure of cell number. The IC 50 (dose which inhibited cell growth by 50%) was calculated assuming the survival rate of uninfected cells to be 100%. The relative dierences in IC 50 s were calculated by dividing the IC 50 of cells infected with Adp16 by the IC 50 of cells infected with AdControl for each cell line.
BrdU incorporation
Cells (3610 6 ) were plated in 15 cm dishes and infected with 50 p.f.u./cell adenoviral vector and incubated at 378C for 48 h. Cells were then pulsed with 10 mM 5-bromodeoxyuridine (BrdU; Sigma Chemical Co., St Louis, MO) for 30 min in IMEM containing 10% FBS. The cells were then harvested by trypsinization, washed in cold PBS, ®xed in cold 70% ethanol, and stored at 7208C. For bivariate analysis of BrdU incorporation across the cell cycle, ®xed cells were pelleted by centrifugation, and treated with pepsin (Boehringer Mannheim Inc., Indianapolis, IN; 0.4 mg/ml in 0.1 M HCl) for 30 min at room temperature, as previously described (Schutte et al., 1987) . After washing in PBT buer (PBS containing bovine serum albumin (BSA) 1 mg/ml, 0.05% Tween-20, pH 7.4) to terminate the enzymatic treatment, cells were resuspended in 2 M HCl and incubated for 30 min at 378C. Cells were washed with borax buer (0.1 M sodium tetraborate, pH 8.5), followed by PBT buer, and incubated with ā uorescein-labeled monoclonal antibody to BrdU (Becton Dickinson Immunocytometry Systems, San Jose, CA) for 45 min. Labeled cells were washed in PBT buer and resuspended in PBS containing 10 mg/ml propidium iodide (Calbiochem-Behring, Inc., San Diego, CA) for 15 min prior to¯ow cytometric analysis. Cells were analysed with a FACSan¯ow cytometer (Becton Dickinson Immunocytometry Systems, San Jose, CA) using doublet discrimination (peak height vs integrated signals).
Immunoprecipitation
Cells (3610 6 ) were plated in 15 cm dishes and infected with 200 u/cell of recombinant adenoviruses for 24 h. Cells were collected by trypsinization, washed twice with PBS, and lysed by incubation at 48C for 20 min in TNN buer containing 40 mM Tris-Cl (pH 8.0), 120 mM NaCl, 0.1 mM sodium orthovanadate, 2 mg/ml aprotinin, 2 mg/ml pepstatin, 2 mg/ml leupeptin and 100 mg/ml phenylmethylsulfonyl uoride. Cell lysates were centrifuged at 12 000 r.p.m. for 15 min at 48C. The supernatants were incubated for 1 h at 48C with 2 mg anti-Cdk4 polyclonal antibody (UBI, New York). Immune complexes were collected on protein ASepharose beads (Pharmacia, Sweden). The beads were washed three times in TNN buer and boiled in SDS sample buer (0.125 M Tris-Cl, pH 6.8; 4% SDS; 10% bmercaptoethanol, and 20% glycerol). Immunoprecipitated proteins were separated by electrophoresis on SDSpolyacrylamide gels and transferred to nitrocellulose. Blots were probed with 3 mg/ml anti-p16 antibody (Ab-2; Santa Cruz, CA), incubated with horse radish peroxidase conjugated to secondary antibody and speci®c complex detected by the enhanced chemiluminescence technique according to the manufacturer's instructions (Amersham, Arlington Heights, IL).
Abbreviations
Cdk, cyclin dependent kinase; CDKI, Cdk inhibitor; MTS1, multiple tumor suppressor 1; Rb, retinoblastoma; Ad, adenovirus; pfu, plaque forming unit; FBS, fetal bovine serum; BrdU, 5-bromo-2'-deoxyuridine; PBS, phosphate buered saline.
